NCT06482073 Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care
| NCT ID | NCT06482073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Lung Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-06-24 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the effectiveness of tumor samples in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.
Eligibility Criteria
Inclusion Criteria: * Subject age 18 years and older * Subject is scheduled/was scheduled for a bronchoscopy or surgical resection as part of standard of care * Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease * Ability to provide blood or saliva sample * Ability to provide archived tissue * Subject is able to understand and adhere to study requirements and able to provide informed consent Exclusion Criteria: * Individuals who have situations that would limit compliance with the study requirements * Institutionalized (i.e. federal medical prison) * Pregnant * Prior germline genetic testing with a 40+ multi-gene panel AND/OR prior somatic tissue (250+ gene) testing utilizing the tissue from the bronchoscopy or surgical resection
Contact & Investigator
Janani S. Reisenauer, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06482073 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06482073 currently recruiting?
Yes, NCT06482073 is actively recruiting participants. Contact the research team at RSTTHORACICRES@mayo.edu for enrollment information.
Where is the NCT06482073 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06482073 clinical trial?
NCT06482073 is sponsored by Mayo Clinic. The principal investigator is Janani S. Reisenauer, M.D. at Mayo Clinic in Rochester. The trial plans to enroll 250 participants.